Prothena appoints Daniel G. Welch as director and Chair Designate

PROTHENA CORP PUBLIC LTD CO

Board expanded to add Daniel G. Welch as director effective Feb 21, 2024; to be proposed as Chair at next AGM.
Welch granted option for 132,000 ordinary shares, vesting over five years at the Feb 21 closing price.
Annual cash retainer of $90,000 as Chair Designate and future Chair, plus standard non-employee director compensation.
Welch will enter standard indemnification agreement; no material interest in any related transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel G. Welch

Director and Chair Designate

PRTA · PROTHENA CORP PUBLIC LTD CO

Effective: 2024-02-21
Filed: February 21, 2024, 6:59 PM ET

On February 21, 2024, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed Daniel G. Welch to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel G. Welch was appointed as Director and Chair Designate at PROTHENA CORP PUBLIC LTD CO.

Action: appointed
Role: Director and Chair Designate

Exact text from the filing

On February 21, 2024, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed Daniel G. Welch to serve as a director of the Company, effective immediately.

View on SEC.gov

PROTHENA CORP PUBLIC LTD CO filing history →

Source: SEC EDGAR

accession 0001559053-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.